Severity
Low
FDA Drug recall · Reported July 17, 2024
Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.
Rising Pharma Holding, Inc. recalled Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories… - a low-severity action.
Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories… was recalled by Rising Pharma Holding, Inc. in July 17, 2024. Reason: Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not co…. Check the official notice for the remedy. Verify recall #D-0599-2024 with the FDA Drug before acting.
The recall
Rising Pharma Holding, Inc. issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not co….
Sourced from official FDA Drug enforcement records. Verify recall #D-0599-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0599-2024) was formally reported on July 17, 2024, with the manufacturer initiating the action on June 24, 2024. It is classified under Low severity (Class III), with a current status of Ongoing. Rising Pharma Holding, Inc. is listed as the recalling firm, operating out of East Brunswick, NJ. Federal records list the affected scope as 868 tubes.
The documented reason for this recall is: Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
868 tubes
Related Recalls
6
5 from same agency
Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories, Inc., Brockton, MA 02301; Mfd. For: Rising Pharmaceuticals, Inc., East Brunswick, NJ 08816 NDC 64980-124-60
Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Ongoing |
| Recall number | D-0599-2024 |
| Date reported | July 17, 2024 |
| Date initiated | June 24, 2024 |
| Recalling firm | Rising Pharma Holding, Inc. |
| Firm location | East Brunswick, NJ |
| Affected scope | 868 tubes |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 17, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.